. Medical and Hospital News .




.
INTERN DAILY
Outside View: Optimistic on biosimilars
by Richard Dolinar
Arlington, Va. (UPI) Apr 27, 2012

disclaimer: image is for illustration purposes only

The U.S. Food and Drug Administration is charged with making new treatments available to patients across the country while also maintaining the highest standards for safety and efficacy. Because of the FDA, Americans can take comfort knowing that innovative treatments and drug therapies have undergone safe and scientifically based drug testing.

A new generation of medicines, known as biologics, are becoming more widely used to treat rheumatoid arthritis, cancer, HIV, Alzheimer's, Parkinson's and many other debilitating diseases. Biologics are advanced prescription drugs that are engineered from living organisms.

Naturally, as they become more popular, manufacturers and patients are seeking ways to increase access to these life-saving and life-enhancing medicines. One way is to allow imitative versions of biologic medicines, known as biosimilars, on to the U.S. market.

Currently the FDA is considering the best way to allow biosimilars on to the market that will ensure patient safety and drug efficacy.

Last week, the FDA received dozens of comments to its draft guidance on the U.S. approval of biosimilars. As the name indicates, biosimilars are similar to but not the same as the brand-name biologic and they will not be available in the United States until the FDA finalizes the draft guidance.

Because biologics are medicines produced from living organisms, they are very different from traditional medication produced from chemicals. Due to that complexity, biologics are quite vulnerable to changes throughout the manufacturing process. Even minor changes could result in versions that are significantly different from the original product.

As such, there are many unanswered questions about biosimilars that remain including how much data are needed be able to declare them safe for use and how will patients react when a biosimilar is substituted for a biologic they have been taking?

Biological products offer incredible potential to improve treatment and patient care but regulatory policies concerning biosimilars must place a premium on patient safety. Biosimilars must be dispensed carefully because they are just that -- similar to a biological product but not an exact copy like a generic drug is to a branded one.

Doctors and patients alike must be aware that there is a difference and not mistakenly believe a biosimilar is equivalent to the original biologic product.

Under the law, after the FDA makes a determination of biosimilarity, manufacturers have the option of presenting additional evidence to the FDA to demonstrate that their biosimilar is so similar to the innovator product that the two are "interchangeable."

The FDA's recently released draft guidance is silent on "interchangeability" other than to say it will be determined sequentially after biosimilarity has been established. It also states that the FDA is continuing to consider the type of information required to establish interchangeability. I caution the FDA to proceed very carefully when making determinations of interchangeability.

States have automatic substitution laws that allow a pharmacist to substitute a generic drug for a brand name one without notifying the patient or prescribing physician. These laws are designed to save money. Since a biosimilar is not identical to its reference product, the FDA and state lawmakers need to tread carefully through this issue.

The FDA can look to other parts of the world where biosimilars are already available. The European Medicines Agency, which regulates biosimilars in Europe, advises that substitution decisions should be made in consultation with the prescribing physician. In addition, automatic substitution is against the law in several European nations; including France, Germany, Sweden and the United Kingdom, among others.

To deliver high-quality healthcare, transparency, facts and information are essential. The patient should have a clear understanding of the differences that exist between biologics and biosimilars and that this isn't your "typical" generic drug. And doctors, in consultation with their patients should determine the best course of treatment for their unique situation.

(Dr. Richard Dolinar is chairman of the Alliance for Safe Biologic Medicines and is a practicing endocrinologist.)

(United Press International's "Outside View" commentaries are written by outside contributors who specialize in a variety of important issues. The views expressed do not necessarily reflect those of United Press International. In the interests of creating an open forum, original submissions are invited.)

Related Links
Hospital and Medical News at InternDaily.com




.
.
Get Our Free Newsletters Via Email
...
Buy Advertising Editorial Enquiries




.

. Comment on this article via your Facebook, Yahoo, AOL, Hotmail login.

Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle



INTERN DAILY
CFR: Universal healthcare requires mandate
Washington (UPI) Apr 24, 2012
The United States is the wealthiest and most powerful nation in the world but when it comes to healthcare coverage, it is only on par with developing nations like Ghana and Brazil, a Council on Foreign Relations report states. The CFR conducted a roundtable discussion Tuesday on the findings of its newly released report - "The New Global Health Agenda: Universal Health Coverage" - whi ... read more


INTERN DAILY
S. Korea nuclear safety agency probes two plants

Construction of Chernobyl shelter starts on anniversary

Sean Penn urges more aid for Haiti

Hong Kong holds nuclear accident drill

INTERN DAILY
First payload ready for next batch of Galileo satellites

NASA Tests GPS Monitoring System for Big US Quakes

SSTL delivers payload for first Galileo FOC satellite

GPS could aid in earthquake warnings

INTERN DAILY
Rio Summit must address population growth: scientists

Scientists show how social interaction and teamwork lead to human intelligence

NIST mini-sensor measures magnetic activity in human brain

Meat eating led to earlier weaning, helped humans spread across globe

INTERN DAILY
Evolution in an island, the secret for a longer life

Nearly Seven million birds die each year at communication towers

Vietnamese held over Philippines turtle catch

Study finds that mild winters are detrimental to butterflies

INTERN DAILY
Dutch okays mutant bird flu study's publication

Rio declares dengue epidemic

Climate right for Asian mosquito to spread in N. Europe

Scientists find members of measles virus family in bats

INTERN DAILY
Chinese blind lawyer escapes house arrest

Chinese activist latest held after Chen escape

China pulls T-shirts featuring premier's quotes

China shuts 'rumour' blogs in Internet crackdown

INTERN DAILY
War planes strike suspected Somali pirate base: coastguard

India proposes norms for Indian Ocean anti-piracy patrols

Iran navy rescues China crew from hijacked freighter

Drones will seek pirates at sea

INTERN DAILY
Outside View: Economy slowing

BoJ eases further as Japan's economy stands still

Spain tightens border in run-up to summit

HSBC says to cut 3,167 jobs in Britain


Memory Foam Mattress Review

Newsletters :: SpaceDaily Express :: SpaceWar Express :: TerraDaily Express :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News

.

The content herein, unless otherwise known to be public domain, are Copyright 1995-2012 - Space Media Network. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement